<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102346">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01688960</url>
  </required_header>
  <id_info>
    <org_study_id>R910-ST-1114</org_study_id>
    <nct_id>NCT01688960</nct_id>
  </id_info>
  <brief_title>Nesvacumab (REGN910/ SAR307746) and Aflibercept (&quot;Ziv-aflibercept&quot; in the U.S.) in Patients With Advanced Solid Malignancies</brief_title>
  <official_title>A Phase 1b Study of Combined Angiogenesis Inhibition by Administering REGN910 and Aflibercept (Ziv-aflibercept) in Patients With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, ascending, multiple dose study of nesvacumab (REGN910/
      SAR307746) in combination with aflibercept (&quot;ziv-aflibercept&quot; in the U.S.)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine the maximum tolerable dose or recommended phase 2 dose of nesvacumab (REGN910/ SAR307746) administered in combination with aflibercept (ziv-aflibercept) in patients with advanced solid malignancies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK)</measure>
    <time_frame>Day 1 to Day 170</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess PK parameters such as concentration of nesvacumab (REGN910/ SAR307746) and aflibercept (ziv-aflibercept).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Day 1 to Day 170</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the anti-drug antibodies of nesvacumab (REGN910/ SAR307746) and aflibercept (ziv-aflibercept)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
    <time_frame>Day 1 to Day 170</time_frame>
    <safety_issue>No</safety_issue>
    <description>Objective tumor response according to RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD)</measure>
    <time_frame>Day 1 to Day 170</time_frame>
    <safety_issue>No</safety_issue>
    <description>Target inhibition biomarker changes, serum tumor markers</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nesvacumab (REGN910/ SAR307746)</intervention_name>
    <description>Dose level 1</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nesvacumab (REGN910/ SAR307746)</intervention_name>
    <description>Dose level 2</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nesvacumab (REGN910/ SAR307746)</intervention_name>
    <description>Dose level 3</description>
    <arm_group_label>Cohort 3a</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aflibercept (ziv-aflibercept)</intervention_name>
    <description>Dose level 1</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3a</arm_group_label>
    <other_name>In US: aflibercept is known as ziv-aflibercept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aflibercept (ziv-aflibercept)</intervention_name>
    <description>Dose level 2</description>
    <arm_group_label>Cohort 3b</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>In US: aflibercept is known as ziv-aflibercept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria include, but are not limited to, the following:

          1. Confirmed diagnosis of solid tumor malignancy

          2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          3. Adequate hepatic, renal and bone marrow function

          4. Resolution of toxicity from prior therapy (except alopecia) to grade less than or
             equal to 1

        Exclusion Criteria:

        Exclusion criteria include, but are not limited to, the following:

          1. Patients with brain metastases, spinal cord compression, carcinomatous meningitis, or
             other evidence of central nervous system involvement

          2. Either systolic BP greater than 140 mm Hg or diastolic BP greater than 90 mm Hg

          3. Patients with medical history of myocardial infarction, unstable angina pectoris,
             coronary/ peripheral artery bypass graft, congestive heart failure or ventricular
             arrhythmia

          4. Patients with deep vein thrombosis or pulmonary embolism within last 3 months

          5. Patients with serious non healing wound or acute ulcer

          6. Patients with treatment resistant or bleeding peptic ulcer disease, erosive
             esophagitis or gastritis, grade 3 or gastrointestinal bleeding/hemorrhage, infectious
             or inflammatory bowel disease, diverticulitis, or other uncontrolled thromboembolic
             event within last 3 months

          7. Patients with history of abdominal or tracheal-esophageal fistula

          8. Prior treatment with aflibercept (ziv-aflibercept), Ang2 or Tie2 inhibitors

          9. Prior treatment with bevacizumab within last 6 weeks

         10. Pregnant or breast-feeding women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 15, 2013</lastchanged_date>
  <firstreceived_date>September 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
